OSE On The Up As Phase III For Cancer Vaccine Is Prepped
French Biotech Trumpets Tedopi Potential In Lung Cancer
OSE’s late-stage ambitions for Tedopi were stalled by the pandemic but the Nantes-based firm has now requested a meeting with the US FDA to get the Phase III program for the anticancer vaccine back on track.
You may also be interested in...
The revenue boost Evusheld has given AstraZeneca over the past year will grind to a halt now that the FDA, as expected, has pulled approval for the antibody combo on the grounds it is ineffective against most SARS-CoV-2 variants circulating in the US.
The UK firm's shareholders have not approved plans to acquire Bioasis, a decision that puts Midatech in a tricky situation as its cash will run out by mid-March.
Hindsight is a wonderful thing but the saga of AstraZeneca's acquisition of CinCor is an eye-opener as SEC filings reveal that a $60 per share offer was rejected in September before a $26 bid won the day earlier this month.